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Epidemiology and aetiology of maternal 
bacterial and viral infections in low- and 
middle-income countries
Background Maternal morbidity and mortality in low and middle 
income countries has remained exceedingly high. However, infor-
mation on bacterial and viral maternal infections, which are impor-
tant contributors to poor pregnancy outcomes, is sparse and poorly 
characterised. This review aims to describe the epidemiology and 
aetiology of bacterial and viral maternal infections in low and middle 
income countries.
Methods A systematic search of published literature was conducted 
and data on aetiology and epidemiology of maternal infections was 
extracted from relevant studies for analysis. Searches were conduct-
ed in parallel by two reviewers (using OVID) in the following data-
bases: Medline (1950 to 2010), EMBASE (1980 to 2010) and Glob-
al Health (1973 to 2010).
Results Data from 158 relevant studies was used to characterise the 
epidemiology of the 10 most extensively reported maternal infec-
tions with the following median prevalence rates: Treponema pallidum 
(2.6%), Neisseria gonorrhoeae (1.5%), Chlamydia trachomatis (5.8%), 
Group B Streptococcus (8.6%), bacterial vaginosis (20.9%), hepatitis 
B virus (4.3%), hepatitis C virus (1.4%), Cytomegalovirus (95.7% past 
infection), Rubella (8.9% susceptible) and Herpes simplex (20.7%). 
Large variations in the prevalence of these infections between coun-
tries and regions were noted.
Conclusion This review confirms the suspected high prevalence of 
maternal bacterial and viral infections and identifies particular dis-
eases and regions requiring urgent attention in public health policy 
planning, setting research priorities and donor funding towards re-
ducing maternal morbidity and mortality in low and middle income 
countries.
Maternal morbidity and mortality in low and middle income countries are 
still unacceptably high. It was estimated that 529 000 maternal deaths oc-
curred throughout the world annually in 2000 (1). This estimate was re-
cently updated with a figure of 273 500 deaths in 2011, the majority of 
which occurred in poor countries (2). The problem of maternal health has 
gained the attention of the global community, as exemplified by United 
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Nations Millennium Development Goal (MDG) 5, which 
is aimed at reducing the maternal mortality ratio by three 
quarters and ensuring universal access to reproductive 
healthcare by 2015 (3). With only 5 years left to achieve 
MDGs, progress towards the maternal health MDG has 
been one of the most disappointing, leading to its being 
highlighted as an urgent global priority at the September 
2010 UN Summit on MDGs (4).
The disparity in maternal health between the developed 
and developing world can be attributed largely to poor ac-
cess and quality of reproductive healthcare in developing 
countries (5). As a result, maternal mortality in developing 
countries remains high due to largely preventable causes 
such as haemorrhage, hypertensive disorders, abortion re-
lated complications and sepsis/infection (6).
An estimated 9.7% of maternal deaths in Africa are due to 
puerperal sepsis (6). Bacterial and viral infections during 
pregnancy contribute towards maternal morbidity and 
mortality and are associated with adverse pregnancy out-
comes including spontaneous abortion, stillbirth, prema-
turity and low birth weight. Furthermore, some infections 
can be transmitted vertically to neonates, leading to subse-
quent neonatal morbidity and mortality (7). Most maternal 
infections can be diagnosed and treated during pregnancy, 
preventing morbidity and mortality of both mother and 
child. The reduction of maternal infections in the develop-
ing world is highly dependent on the effective use of lim-
ited health resources to diagnose and treat these infections.
The planning of effective public health measures is cur-
rently limited by the lack of information available on the 
precise epidemiology and aetiology of bacterial and viral 
maternal infections. Lack of information can also negative-
ly impact donor interest and international commitment. 
This review aims to summarize published literature on the 
aetiology and epidemiology of bacterial and viral maternal 
infections in low and middle income countries. Addition-
ally, the review aims to identify gaps in available informa-
tion on the subject. This epidemiological information can 
subsequently be used to identify similarities and differenc-
es in the causes of maternal infection within and between 
geographic regions, and to guide local and international 
public health initiatives to reduce the prevalence and bur-
den of these infections.
METHODS
Literature search terms
Initial searches were conducted to identify suitable keywords 
and MeSH headings to use in the final search (Table 1). The 
search strategy was prepared with input from a librarian. 
Searches were conducted in parallel by two reviewers (us-
ing OVID) in the following databases on 1 August 2010: 
Medline (1950 to August Week 4 2010), EMBASE (1980 
to 2010 Week 30) and Global Health (1973 to August 
2010).
Study inclusion and exclusion criteria
Studies were screened by title and then by abstract for rel-
evance. Studies were deemed relevant if they provided in-
formation on the aetiology or epidemiology of bacterial and 
viral infections in pregnant women in developing coun-
tries. These studies were then grouped according to patho-
gen studied, with some studies providing information on 
multiple pathogens. Studies providing information on the 
epidemiology of parasitic infections in pregnant women 
were identified but not analyzed, as they were addressed 
in a separate review. Studies reporting the prevalence of 
maternal HIV infection were identified but not included 
for analysis, as this information is available through other 
sources. Relevant English language papers were analyzed 
Table 1 Search terms used to identify published articles on the 
prevalence and etiology of maternal infections in the developing 
world
exp Infection/
AND
exp Pregnancy/ OR exp Pregnancy Complications, Infectious/
AND
exp Developing Countries OR africa/ or africa, northern/ or algeria/ or egypt/ 
or libya/ or morocco/ or tunisia/ or “africa south of the sahara”/ or africa, 
central/ or cameroon/ or central african republic/ or chad/ or congo/ or 
“democratic republic of the congo”/ or gabon/ or africa, eastern/ or burun-
di/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or somalia/ or 
sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ 
or lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swa-
ziland/ or zambia/ or zimbabwe/ or africa, western/ or benin/ or burkina 
faso/ or cape verde/ or cote d’ivoire/ or gambia/ or ghana/ or guinea/ or 
guinea-bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or sen-
egal/ or sierra leone/ or togo/ or caribbean region/ or west indies/ or “anti-
gua and barbuda”/ or cuba/ or dominica/ or dominican republic/ or gre-
nada/ or guadeloupe/ or haiti/ or jamaica/ or martinique/ or “saint kitts and 
nevis”/ or saint lucia/ or “saint vincent and the grenadines”/ or central amer-
ica/ or belize/ or costa rica/ or el salvador/ or guatemala/ or honduras/ or 
nicaragua/ or panama/ or latin america/ or mexico/ or south america/ or ar-
gentina/ or bolivia/ or brazil/ or chile/ or colombia/ or ecuador/ or french 
guiana/ or guyana/ or paraguay/ or peru/ or suriname/ or uruguay/ or ven-
ezuela/ or asia/ or asia, central/ or kazakhstan/ or kyrgyzstan/ or tajikistan/ 
or turkmenistan/ or uzbekistan/ or asia, southeastern/ or borneo/ or brunei/ 
or cambodia/ or east timor/ or indonesia/ or laos/ or malaysia/ or mekong 
valley/ or myanmar/ or philippines/ or thailand/ or vietnam/ or asia, west-
ern/ or bangladesh/ or bhutan/ or india/ or sikkim/ or middle east/ or af-
ghanistan/ or iran/ or iraq/ or jordan/ or lebanon/ or syria/ or turkey/ or ye-
men/ or nepal/ or pakistan/ or sri lanka/ or far east/ or china/ or tibet/ or 
“democratic people’s republic of korea”/ or mongolia/ or taiwan/ or atlantic 
islands/ or azores/ or albania/ or lithuania/ or bosnia-herzegovina/ or bul-
garia/ or byelarus/ or “macedonia (republic)”/ or moldova/ or montenegro/ 
or romania/ or russia/ or bashkiria/ or dagestan/ or moscow/ or siberia/ or 
serbia/ or ukraine/ or yugoslavia/ or armenia/ or azerbaijan/ or “georgia (re-
public)”/ or indian ocean islands/ or comoros/ or madagascar/ or mauritius/ 
or reunion/ or seychelles/ or fiji/ or papua new guinea/ or vanuatu/ or guam/ 
or palau/ or “independent state of samoa”/ or tonga/
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in this work, along with the Chinese electronic databases, 
with the intention of translating and analyzing non-English 
papers, too. The inclusion criteria were:
Subjects: Pregnant women at any stage of pregnancy or la-
bour, including the puerperium (up to 42 days after labour);
Study location: Low and middle income countries (as de-
fined by The World Bank in 2010);
Study design and sampling methods: No restrictions ap-
plied;
Data collection: Only studies that provided evidence of 
bacterial or viral infection using microbiological or sero-
logical test results were included;
Results: Papers were selected if they provided information 
on the burden of a particular pathogen (the prevalence of 
a particular infection in pregnant women in the commu-
nity over time/incidence) and/or the aetiology of bacterial 
and viral maternal infections (prevalence of a specific 
pathogen/infection).
Quality criteria
Only studies with more than 500 subjects were included, 
because we wanted to protect strongly against implausible 
proportional contributions of certain pathogens which 
could have occurred due to chance in smaller data series. 
Papers were required to describe their samples and meth-
ods in detail, and provide microbiological or serological 
evidence of the aetiology of infection.
Data extraction
Information on pathogen studied, sample population 
(pregnant women studied during pregnancy or at labour) 
and size, study setting, duration and type, microbiological/
serological test used and results were extracted from ab-
stracts and full papers for analysis.
Data analysis
Epidemiology and aetiology of bacterial and viral maternal 
infections were summarized according to the pathogen 
studied. Only pathogens with 5 or more studies reporting 
on its epidemiology and/or aetiology were analyzed. Me-
dian prevalence of each infection was calculated and trends 
in the prevalence of maternal infections were noted.
Selection of studies
The final search yielded 8580 relevant titles. Figure 1 out-
lines the results of the search process and application of 
inclusion and exclusion criteria, resulting in the final pan-
el of studies from which data was extracted.
Studies retained for data extraction (n=158) characterized 
the prevalence of 5 bacterial pathogens (Treponema palli-
dum, Neisseria gonorrhoeae, Chlamydia trachomatis, Group 
B Streptococcus, bacterial vaginosis) and 5 viral pathogens 
(hepatitis B virus, hepatitis C virus, Cytomegalovirus, Ru-
bella, Herpes simplex) among pregnant women in develop-
ing countries, with three further reports providing second-
ary cross-sectional insights or reviews of the literature in 
this field which were considered useful (8–168). Studies 
reporting prevalence maternal HIV infection (n=167) were 
not included in the analysis.
RESULTS
Prevalence of bacterial infections
Syphilis (Treponema pallidum). Seventy-two studies char-
acterizing the prevalence of maternal syphilis in 36 devel-
oping countries were identified (Supplementary Table 1). 
The features and results of these studies are summarised in 
Figures 2–5.
In terms of study design, 58.3% of the identified studies 
were cross sectional, whilst 18.1% were screening studies. 
The majority of the studies (90.3%) were conducted in 
healthcare facilities (58.3% in antenatal or prenatal clinics), 
suggesting either awareness towards the need for antenatal 
screening for maternal syphilis infection, or merely that it 
is much easier to recruit study subjects in health care fa-
cilities. The remaining studies (5.6%) were community-
based and the study setting was not specified in 4.2%.
Rapid Plasma Reagent (RPR) testing was used to detect anti-
treponemal antibodies in many studies (49%), often in com-
bination with another test, most commonly the Treponema 
 
 
 
  
Search conducted
8580 titles retrieved
1565 titles retained
Titles screened for relevance
Abstracts available screened 
for relevance
Quality criteria applied
38 non-English  
studies retained for 
future analysis
158 studies retained for data extraction; 
sorted according to pathogen studied (a pathogen  
was only studied if there were 5 or more papers  
reporting the epidemiology of the pathogen)
Figure 1 Summary of the literature search.
499 studies that provide information 
on bacterial and viral infections (except HIV)  
in pregnant women identified
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pallidum Haemagglutination Assay (TPHA) (Figure 4). This 
is because RPR is cheap and simple to perform, but false 
positive results are common, necessitating confirmatory test-
ing (7). Particularly high prevalence of maternal syphilis was 
reported in studies from Cameroon, South Africa and Zim-
babwe (around 15.0%). Both studies from Cameroon were 
conducted in the Yaounde province, and show an increase 
in the prevalence of maternal syphilis from 15.9% in 1992 
to 17.4% in 1998 (17,66,107,130).
Gonorrhoea (Neisseria gonorrhoeae). Twenty-one stud-
ies providing information of the prevalence of maternal 
Neisseria gonorrhoeae infection were identified (Supple-
mentary table 2). The characteristics of these studies and 
the prevalence reported are summarized in the Figures 
6–9.
With regards to study design, 20 studies (95.2%) were 
cross sectional and 1 was a randomized controlled trial 
(data from the control group was extracted). The majority 
of the studies (80.9%) were carried out in healthcare fa-
cilities and a minority was community-based (19.1%). Me-
dian prevalence of maternal gonococcal infection was rela-
tively low, at 1.5% (Figure 9). However, higher prevalence 
of maternal gonococcal infection was reported in studies 
from Mongolia (6.1%), Vanuatu (5.9%) and Zimbabwe 
(5.8%) suggesting the need for targeted action in these 
countries (12,79,145).
Chlamydia trachomatis. Nineteen studies reporting the 
prevalence of maternal Chlamydia trachomatis (CT) infec-
tion were identified (Table 2).
These studies diagnosed maternal infection by detecting 
antibodies towards C. trachomatis or by pathogen detection 
in urine samples or endocervical swabs using PCR. The 
median prevalence of maternal C. trachomatis infection is 
5.80%. Particularly high prevalence of maternal C. tracho-
Figure 2 Geographical distribution of studies (n=72) reporting the 
prevalence of maternal syphilis; “no data” in the legend refers to low and 
middle-income countries only, as data from high-income countries were 
not the subject of this study.
Figure 3 Distribution according to the size of 
population studied in 72 studies reporting 
maternal syphilis prevalence.
Figure 4 Techniques used to diagnose maternal syphilis in the 
72 studies identified. TRUST – Toluidine red unheated serum 
test; TPPA – Treponema pallidum particle agglutination test; 
TPHA – Treponema pallidum haemagglutination test; FTA-ABS 
– Fluorescent treponemal antibody absorption; VDRL – Venere-
al Disease Research Laboratory test; RPR – Rapid Plasma 
Reagent; ICS – immunochromatographic strip.
Figure 5 Box plot of syphilis prevalence reported by the 72 
relevant studies. All studies measured prevalence by detecting 
the presence of antibodies to Treponema pallidum. The following 
number summaries are depicted in the boxplot: the smallest 
observation (sample minimum), lower quartile (25%), median 
(50%), upper quartile (75%), and largest observation (sample 
maximum). Asterisks indicate outliers.
Prasad Palani Velu et al.
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Table 2 Characteristics and results of studies (n=19) reporting prevalence of maternal Chlamydia trachomatis infection
Article
Location,
setting of study
Type, duration of study Population Results / Prevalence Technique used
Msuya et al, 2009 
(100)
Tanzania, 2 primary  
health clinics
Cross sectional study,  
21 months
2654 pregnant women 17.5%
ELISA detecting 
anti-chlamydial IgG
Jalil et al, 2008 (63)
Brazil, prenatal services  
in 6 cities
Cross sectional study,  
1 year
3003 pregnant women CT prevalence of 9.4% 
Hybrid capture 
technique
Kinoshita-Moleka  
et al, 2008 (70)
Democratic Republic  
of Congo, 2 maternity clinics
Cross sectional study,  
4 months
529 pregnant women 1.7% PCR
Lujan et al, 2008 (89) Mozambique, antenatal clinic
Cross sectional study,  
5 months
835 first void urine samples  
from pregnant women
4.1% PCR
Romoren et al, 2007 
(127)
Botswana, antenatal clinic
Cross sectional study,  
singular time point
703 pregnant antenatal  
care attendees
8% prevalence
LCR
Chen et al, 2006 (27) China, antenatal clinic
Cross sectional study,  
3 months
504 pregnant women 10.1% PCR
Thammalangsy  
et al, 2006 (156)
Laos, 2 hospitals
Cross sectional study,  
7 months
500 antenatal attendees
10.2% by nucleic acid  
hybridisation and 9.6% by PCR
Nucleic acid hybrid-
isation, PCR
Amindavaa et al, 2005 
(12)
Mongolia, prenatal clinics
Cross sectional survey,  
11 months
2000 pregnant women 19.3% PCR
Apea-Kubi et al, 2004 
(14)
Ghana, gynaecology clinics  
at teaching hospital
Cross sectional study,  
singular time point
517 pregnant women 3% prevalence RNA detection kit
Sullivan et al, 2003 
(145)
Vanuatu, antenatal clinic
Cross sectional study,  
12 months
547 pregnant women 21.5% PCR
Gray et al, 2001 (53) Uganda, community based
Randomised control trial, 
duration not specified
1576 pregnant women 
 in the control arm of the study
2.7% LCR
Mayank et al, 2001 
(97)
India, community based
Cross sectional study,  
duration not specified
600 pregnant women 4.3% ELISA
Latif et al, 1999 (79)
Zimbabwe, Antenatal and  
primary care clinics
Cross sectional study
1189 asymptomatic pregnant  
women
5.8% (and/or  
Gonococcal infection)
Not specified
Mulanga-Kabeya  
et al, 1999 (101)
Mali, community based
Cross sectional study,  
1 month
549 pregnant women 5.0% EIA
Bourgeois et al, 1998 
(21)
Gabon, 3 antenatal clinics
Cross sectional study,  
5 months
646 pregnant women 9.9% EIA
Kilmarx et al, 1998 
(69)
Thailand, antenatal clinics
Cross sectional study,  
singular time point
500 pregnant mothers in Chiang Rai, 
521 pregnant mothers in Bangkok
5.70% prevalence
PCR
Diallo et al, 1997 (38) Ivory Coast, antenatal clinic
Cross sectional study,  
4 months
546 pregnant women 5.5% Culture, EIA
Meda et al¸ 1997 (98)
Burkina Faso,  
2 antenatal clinics
Cross sectional study,  
duration not specified
645 pregnant women 3.1% EIA
Joesoef et al, 1996 (65) Indonesia, prenatal clinic
Cross sectional study,  
15 months
599 pregnant women 8.2%
Direct immuno-flu-
orescence
EIA – enzyme immunoassay, ELISA – enzyme-linked immunosorbent assay, LCR – ligase chain reaction, PCR – polymerase chain reaction
Table 3 Characteristics and results of studies (n=12) reporting prevalence of maternal Group B Streptococcus (GBS) colonisation
Article
Location,
setting of study
Type, duration of study Population Results / Prevalence
Technique 
used
Seoud et al, 2010 (134) Lebanon, 3 hospitals
Cross sectional study,  
8 months
775 pregnant mothers
17.7% positive for GBS  
colonisation
Not specified
Mavenyengwa et al, 2010 (96)
Zimbabwe,  
3 communities
Cohort study, duration 
not specified
780 women (one or  
more samples collected)
60.3% positive for GBS  
colonisation
Culture
Mansouri et al, 2008 (94)
Iran, 3 major  
non-private hospitals
Cross sectional study,  
11 months
602 pregnant women  
at childbirth
9.1% were colonised  
by GBS
Culture
Namavar et aI, 2008 (105) Iran, hospital
Cross sectional study,  
6 months
1197 pregnant women  
at labour
9.1% had rectovaginal  
colonisation with GBS
Culture
Zusman et al, 2006 (168) Brazil, 2 hospitals
Prospective study,  
5 months
598 pregnant women
17.9% maternal  
colonisation rate
Culture
Goto et al, 2005 (52)
Vietnam,  
community based
Survey, duration not 
specified
505 pregnant women 4% Culture
Larcher et al, 2005 (78) Argentina, hospital
Prospective study,  
18 months
1228 pregnant women
1.4% maternal  
colonisation rate
Culture
Sidky & Thomas, 2002 (139) UAE, hospital
Cross sectional study,  
2 months
891 pregnant women  
at delivery
21.5% maternal  
colonisation rate
Culture
Toresani et al, 2001 (158) Argentina, hospital
Cross sectional study,  
25 months
531 pregnant women
3.2% were  
positive for GBS
Culture
Werawatakul et al, 2001 (164) Thailand, hospital
Cross sectional study,  
5 months
902 pregnant women  
presenting at labour
6.2% maternal  
colonisation rate
Culture
Ocampo-Torres et al, 2000 
(111)
Mexico, 3 public  
hospitals
Cross sectional study,  
8 months
910 pregnant  
women at delivery
8.6% GBS  
colonisation rate
Culture, Latex 
agglutination
Olanisebe & Adetosoye, 1986 
(113)
Nigeria, 4  
government hospitals
Cross sectional study, 
duration not specified
500 pregnant women  
(2nd and 3rd trimester)
1.6% positive for GBS Culture
UAE – United Arab Emirates
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matis infection was identified in Vanuatu (21.5%), Mongo-
lia (19.3%) and Tanzania (17.5%) (12,100,145).
Group B Streptococcus. Twelve studies reporting the prev-
alence of maternal Group B Streptococcus (GBS) (S. agalac-
tiae) colonisation were identified (Table 3).
The majority of studies diagnosed GBS colonization by di-
rect culture of vaginal swabs. Median prevalence of mater-
nal GBS colonization was 8.85%. The highest prevalence 
of maternal GBS colonization reported was 60.3% in 3 
communities across Zimbabwe, which was significantly 
higher than the prevalence reported by other studies. How-
ever this prevalence was reported as not significantly asso-
ciated with adverse perinatal outcomes (96). Higher prev-
alence was also noted in Lebanon and the United Arab 
Emirates (136,139).
Bacterial vaginosis. Eleven studies reported the preva-
lence of bacterial vaginosis (Table 4).
Figure 8 Size of study populations in 21 studies identified 
reporting maternal gonococcal infection prevalence.
Figure 9 Prevalence of N. gonorrhoeae  detected in relevant studies 
(n=21). All studies measured prevalence by detecting the 
infecting organism in pregnant women. The following number 
summaries are depicted in the boxplot: the smallest observation 
(sample minimum), lower quartile (25%), median (50%), upper 
quartile (75%), and largest observation (sample maximum).
The median prevalence of maternal bacterial vaginosis was 
20.9%. Especially high prevalence was reported in Uganda, 
Botswana and Zimbabwe, highlighting high prevalence of 
bacterial vaginosis in sub-Saharan Africa. The majority of 
studies used microscopy of vaginal wet mounts in combi-
nation with established criteria for diagnosing bacterial 
vaginosis (53,75,126).
Prevalence of Viral Pathogens
Hepatitis B virus. Thirty-nine studies characterizing the 
prevalence of maternal Hepatitis B infection were identified 
(Supplementary Table 3), and their features and results 
are summarized in Figures 10–13.
The majority of identified studies were conducted in a 
healthcare facility (87.2%) whilst 5.1% were community 
based and 7.7% of studies did not specify the setting. Most 
of the studies were also cross sectional (69.2%) in nature, 
with remaining studies being retrospective observational 
Figure 6 Geographical distribution of studies (n=21) reporting 
prevalence of maternal gonococcal infection; “no data” in the 
legend refers to low- and middle-income countries only, as data 
from high-income countries were not the subject of this study.
Figure 7 Techniques used to identify gonococcal infection in the 
21 studies identified (LCR – ligase chain reaction).
Prasad Palani Velu et al.
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Table 4 Characteristics and results of studies (n=11) reporting prevalence of bacterial vaginosis in pregnant women
Article
Location,
setting of study
Type, duration of study Population
Results / 
Prevalence
Technique used
Kurewa et al, 2010 (75)
Zimbabwe,  
peri-urban clinics
Cross sectional study,  
19 months
691 pregnant women 32.6% Amsel’s criteria
Msuya et al, 2009 (100)
Tanzania,  
2 primary health clinics
Cross sectional study,  
21 months
2654 pregnant women 20.9% Amsel’s criteria
Kirakoya-Samadoulougou 
et al, 2008 (71)
Burkina Faso,
4 primary health centres
Cross sectional study,  
3 months
2133 pregnant women  
with analysable data
6.4%
Nugent scoring 
method
Romoren et al, 2007 (127)
Botswana, multiple 
antenatal clinics
Cross sectional study,  
5 months
703 pregnant women 38.0% Microscopy
Azargoon & Darvishzadeh, 
2006 (16)
Iran, hospital
Cohort study,  
duration not specified
1223 pregnant women 16.0%
Vaginal pH,  
saline wet mount, 
Amsel tests
Thammalangsy  
et al, 2006 (156)
Laos, 2 hospitals
Cross sectional study,  
7 months
500 pregnant antenatal 
attendees
14.4% by Amsel’s 
criteria and 22.0% 
by Nugent’s score
Amsel’s criteria, 
Nugent’s score
Goto et al, 2005 (52) Vietnam, community based
Survey, duration not 
specified
505 pregnant women  
in 10 communes
7% Nugent criteria
Gray et al, 2001 (53) Uganda, community based
Randomised control trial, 
duration not specified
1576 pregnant women in  
the control arm of the study
48.5% Microscopy
Mayank et al, 2001 (97) India, community based
Cross sectional study, 
duration not specified
600 pregnant women
18%
Microscopy
Taha et al, 1999 (150) Malawi, hospital
Cross sectional study,  
25 months
9126 pregnant women 30%
Vaginal wet 
mounts
Meda et al, 1997 (98)
Burkina Faso,  
2 antenatal clinics
Cross sectional study, 
duration not specified
645 pregnant women 13% Microscopy
Figure 10 Geographical distribution of studies (n=39) providing 
information on prevalence of maternal hepatitis B virus (HBV) 
infection; “no data” in the legend refers to low and middle-income 
countries only, as data from high-income countries were not the 
subject of this study.
Figure 11 Techniques used to identify hepatitis B 
virus (HBV) infection in 39 studies.
Figure 12 Sizes of study populations in 39 studies reporting 
maternal hepatitis B virus (HBV) infection prevalence.
Figure 13 Box plot showing prevalence of hepatitis B virus (HBV) 
infection detected in relevant studies (n=37). Only 30 of 37 
relevant studies measured prevalence by detecting hepatitis B 
surface antigen (HBsAg) in pregnant women. The following 
number summaries are depicted in the boxplot: the smallest 
observation (sample minimum), lower quartile (25%), median 
(50%), upper quartile (75%), and largest observation (sample 
maximum). Asterisk indicates an outliner.
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(17.9%), surveys (5.1%) and either prospective, cohort or 
case control studies (2.5% each).
The majority of studies screened for the presence of mater-
nal HBV infection by detecting Hepatitis B surface antigen 
(HBsAg) in maternal serum. Particularly high maternal 
HBV prevalence (25%) was identified in Zimbabwe (90), 
Brazil (20) and Taiwan (83).
Hepatitis C virus. Twenty-one studies reporting the preva-
lence of maternal Hepatitis C virus (HCV) infection were 
identified (Supplementary Table 4). The features and find-
ings of these studies are summarized in Figures 14 to 17.
Almost all studies reporting maternal HCV prevalence were 
conducted in healthcare facilities (95.2%) and one did not 
specify the study setting. The majority of studies were also 
cross sectional (80.9%), with the remaining studies being 
case control studies (14.3%), prospective studies (9.5%) 
and one serological survey (4.8%).
Median maternal exposure to HCV (anti-HCV) prevalence 
reported was 1.4%. Active infection prevalence (HCV 
RNA) was reported in 6 studies and median active HCV 
infection prevalence from these studies was 1.2%. Two 
studies from Egypt reported especially high prevalence of 
maternal HCV exposure (15.8% and 15.7%) and active in-
fection rates (10.8% and 10.9%), highlighting a local prob-
lem with maternal HCV infection in Egypt (136,143).
Rubella virus. Fifteen studies characterizing the epidemi-
ology of maternal rubella were identified (Table 5).
These studies detected the presence of maternal anti-rubel-
la IgG as a marker of past infection or immunization and 
mothers who did not possess these antibodies were suscep-
tible to rubella infection. Maternal IgM was detected in 
some studies as a marker of recent or current infection, 
which is associated with an increased risk of vertical trans-
mission. Median maternal susceptibility to rubella was 
Table 5 Characteristics and results of studies (n=15) reporting prevalence of maternal rubella infection
Article
Location,
setting of study
Type, duration of 
study
Population Results / Prevalence Technique used
Lin 
et al, 2010 (86)
Taiwan, hospital
Cross sectional study,  
7 years
10,089 pregnant women Seronegativity was 14.0% Microparticle EIA
Tamer  
et al, 2009 (152)
Turkey, antenatal 
clinic
Cross sectional study, 
duration not specified
1972 serum samples from 
pregnant women
Seropositivity for anti-rubella 
IgG, IgM and IgG+IgM together 
was 96.1%, 0.2% and 1.8%, 
respectively
Commercial 
ELISA (detecting 
IgG and IgM)
Ai & Ee, 2008 (8)
Malaysia, antenatal 
clinics and hospital
Cross sectional study, 
duration not specified
500 pregnant mothers
11.4% were susceptible to 
Rubella
Rubella IgG 
studies
Majlessi  
et al, 2008 (92)
Iran, health centres
Cross sectional study,  
2 years
965 pregnant women
Estimated rubella immunity rate 
was 91.1%, Nonimmunity rate 
was 8.9%
ELISA
Das et al, 2007 
(34)
India, hospital
Screening, duration  
not specified
1115 pregnant women with bad 
obstetric history, 500 normal 
pregnant women
3.6% seropositivity (*BOH), 0% 
seropositivity (normal)
ELISA (Detecting 
IgM)
Ocak et al, 2007  
(110)
Turkey, antenatal 
clinic
Retrospective 
observational,  
23 months
1652 pregnant women
Anti-rubella IgG and IgM 
antibodies were reactive in 
95.0%, and in 0.54%
ELISA (detecting 
IgG and IgM)
Pehlivan  
et al, 2007 (119)
Turkey,  
community based
Cross sectional  
study, 7 months
824 women from 60 clusters; 
803 eligible for serological study
93.8% positive for anti-rubella 
IgG, 0.6% were IgM and IgG 
positive, 5.6% were susceptible
Micro ELISA 
(detecting IgG 
and IgM)
Tseng  
et al, 2006 (160)
Taiwan, hospital
Retrospective 
observational, 4 years
5007 pregnant women
13.4% susceptible among 
Taiwanese women; 29.1% 
susceptible among non-
Taiwanese women
Microparticle EIA
Barreto  
et al, 2006 (18)
Mozambique, 
antenatal clinics
Cross sectional 
serosurvey, 3 months
974 pregnant women at 
antenatal clinic attendance
95.3% positive for Rubella IgG ELISA
Corcoran & 
Hardie, 2006 (31)
South Africa, 
antenatal clinics
Cross sectional study, 
duration not specified
1200 serum samples from a 
2003 HIV/syphilis survey
96.5% immune ELISA
Desinor  
et al, 2004 (36)
Haiti, hospital
Cross sectional  
study, 4 months
503 pregnant women; 8 
excluded leaving 495
95.2% were seropositive
EIA
Weerasekera  
et al, 2003 (163)
Sri Lanka,  
antenatal clinic
Cross sectional  
study, 2 years
500 maternal blood samples, 
before 16th week of gestation
82% were positive for rubella 
specific IgG, 75% gave a history 
of vaccination against rubella 
before their present pregnancy
ELISA (detecting 
IgG and IgM)
Palihawadana  
et al, 2003 (116)
Sri Lanka, multiple 
antenatal clinics
Cross sectional study, 
duration not specified
620 pregnant women
76% of pregnant females were 
seropositive
ELISA (detecting 
IgG)
Ashrafunnessa 
Khatun, et al, 2000 
(15)
Bangladesh, 
hospital
Cross sectional  
study, 11 months
609 pregnant women
85.9% were seropositive and 
14.1% were seronegative
ELISA
Dos Santos  
et al, 2005 (39)
Brazil, prenatal 
testing
Cross sectional  
study, 8 months
1024 pregnant women 77.4%
Haemagglutinin 
Inhibition Assay
EIA – enzyme immunoassay, ELISA – enzyme-linked immunosorbent assay
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8.9%. Higher susceptibility rates were reported in Sri Lan-
ka, Brazil and Taiwan (2 studies) (39,84,160,163).
Cytomegalovirus. Five studies on maternal cytomegalovi-
rus (CMV) infection prevalence were identified (Table 6).
The median prevalence of maternal IgG to CMV (calculat-
ed from 4 studies that reported this) was 95.7%, indicating 
a high proportion of mothers with previous exposure to 
CMV. One hospital-based study in India identified a statis-
tically significant higher prevalence of CMV IgM (indicat-
ing active or recent infection) in mothers with Bad Obstet-
ric History (BOH), highlighting a role for maternal CMV 
infection in adverse pregnancy outcome in this setting (34).
Herpes simplex virus. Five studies outlining the preva-
lence of maternal Herpes simplex virus 2 (HSV-2) were 
identified (Table 7).
These studies detected the presence of antibodies to HSV 
as a marker of maternal infection. Median prevalence of 
HSV-2 was 20.7%. Higher seroprevalences were noted in 
Zimbabwe, Vanuatu and Tanzania (56,75,166).
DISCUSSION
Prevalence of bacterial and viral maternal 
infections
Our search of published literature relevant to the aetiology 
and epidemiology of bacterial and viral maternal infections 
in the developing world retrieved 499 titles. Analysis of 
these titles yielded 158 studies which provided detailed 
epidemiological information on 10 maternal infections. 
The 5 bacterial and 5 viral maternal infections identified in 
this panel represent maternal infections that were most ex-
tensively studied, suggesting that these infections have a 
high burden on pregnancy outcomes in the developing 
world. These infections also have potential adverse effects 
on neonates.
Our review confirms the suspected high prevalence of bac-
terial and viral maternal infections in the developing world, 
as demonstrated by the median prevalence rates calculated 
for each pathogen studied. Of particular concern are the 
Figure 14 Geographical distribution of studies (n=21) providing 
reporting prevalence of maternal hepatitis C (HCV) infection; “no data” 
in the legend refers to low and middle-income countries only, as data 
from high-income countries were not the subject of this study.
Figure 15 Techniques used to diagnose maternal hepatitis 
C (HCV) infection (n=21 studies); HCV RNA refers to 
tests detecting HCV RNA, including PCR and RT-PCR.
Figure 16 Size of study populations of 21 studies reporting 
maternal hepatitis C (HCV) infection prevalence.
Figure 17 Box plot showing prevalence of hepatitis C virus (HCV) 
exposure detected in relevant studies (n=21). All studies diagnosed 
the history of HCV infection by detecting anti-HCV antibodies in 
serum. The following number summaries are depicted in the 
boxplot: the smallest observation (sample minimum), lower 
quartile (25%), median (50%), upper quartile (75%), and largest 
observation (sample maximum). Asterisk indicates an outlier.
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high prevalence rates of maternal syphilis (2.6%), C. tra-
chomatis (5.8%), bacterial vaginosis (20.9%), hepatitis B 
virus (4.3%) and Herpes simplex virus (20.7%).
The prevalence of these infections also showed significant 
variance between countries and regions. The prevalence of 
maternal infections in sub-Saharan Africa is especially high, 
specifically in Zimbabwe (75,79,96,130), Tanzania (101, 
166) and Cameroon (66,107). Previous studies have shown 
that all-cause obstetric risk and maternal mortality ratio are 
highest in Sub-Saharan Africa (1). The high prevalence of 
maternal infections in this region may have an important 
contributory role towards the high maternal morbidity and 
mortality seen in Sub-Saharan Africa. Regional differences 
in the prevalence of maternal infections are likely to be 
closely related to the quality of reproductive healthcare 
available in different regions, or unique local scenarios.
Gaps in existing knowledge
In the process of reviewing the subject, we identified sev-
eral facility-based retrospective studies reporting causes of 
maternal mortality. Many of these studies attributed a pro-
portion of deaths to infection or sepsis, but were unable to 
provide microbiological or serological evidence of the spe-
cific aetiology of infection. Thus, these studies had to be 
excluded from the final panel of studies that we reviewed. 
This highlights a gap in existing knowledge on the epide-
miology and impact of maternal infection, especially on the 
aetiology of infectious agents that lead to puerperal sepsis 
and subsequent mortality. Increased surveillance and diag-
nostic capabilities in healthcare facilities and in the com-
munity is needed to identify the aetiological agents respon-
sible for puerperal sepsis and maternal mortality.
The prevalence of maternal infection reported by the stud-
ies identified in this review may be an underestimate of ac-
tual rates of infection as not all pregnant women in devel-
oping countries may have access to or choose to access 
formalized antenatal care. This could be due to financial 
constraints, difficulties in accessing these facilities and per-
sonal or cultural beliefs. In addition, antenatal care servic-
es may not have the capacity to routinely screen for mater-
nal infections, especially those that are asymptomatic (such 
as N. gonorrhoeae and C. trachomatis) and those that require 
serological tests such as PCR and ELISA to diagnose (Hep-
Table 6 Characteristics and results of studies (n=5) reporting prevalence of maternal cytomegalovirus (CMV) infection
Article
Location,
setting of study
Type, duration of 
study
Population Results / Prevalence Technique used
Tabatabaee 
et al, 2009 
(149)
Iran, hospital
Cross sectional study, 
7 months
1472 pregnant women present-
ing at labour
97.69% seropositivity, 2.31% 
seronegativity; prevalence of active 
infection – 4.35% 
Not specified
Das et al, 
2007 (34)
India, hospital Cross sectional study
1115 pregnant women with Bad 
obstetric history, 500 normal 
pregnant women
11% prevalence in women with Bad 
obstetric history, 4% prevalence in 
normal pregnant women
Commercial ELISA kit 
detecting anti-CMV IgM
Ocak et al, 
2007 (110)
Turkey, hospital
Retrospective 
observational study, 
2 years
1652 pregnant women
94.9%seropositivity for anti-CMV 
IgG, 0.4%positive for anti-CMV IgM
ELISA detecting anti-
CMV IgG and IgM
Suarez et al, 
1994 (144)
Chile, public 
outpatient depart-
ment and a special 
clinic for university 
students
Cross sectional study, 
3 years
939 pregnant women of a low 
socioeconomic level, and 123 
pregnant university students
95% in low socioeconomic class; 
69.9% in pregnant students; 2 
primary infections occurred (1 in 
each group)
ELISA; initially seroneg-
ative women were tested 
again during 2nd and 
3rd trimester to identify 
primary infections
Tamer et al, 
2009 (152)
Turkey, antenatal 
clinics
Cross sectional study, 
singular time point
1972 samples of sera from 
pregnant women
Seroprevalence of anti-CMV IgG, 
IgM and IgG+IgM together were 
found in 96.4%, 0.7% and 1.9% of 
the pregnant women, respectively
Commercial ELISA kit
ELISA – enzyme-linked immunosorbent assay
Table 7 Characteristics and results of studies (n=5) reporting prevalence of maternal Herpes simplex virus (HSV) infection
Article
Location,
setting of study
Type, duration of study Population Results / Prevalence Technique used
Kurewa et al, 2010 (75)
Zimbabwe,  
peri-urban clinics
Cross sectional study,  
19 months
691 pregnant women 51.10% seropositive ELISA detecting IgG
Yahya-Malima et al, 2008 
(166)
Tanzania,  
antenatal clinics (6)
Cross sectional study, 
duration not specified
1296 sera collected from 
pregnant women
20.7% prevalence  
of genital herpes ELISA
Chen et al, 2007 (28)
China,  
antenatal clinic
Cross sectional study,  
3 months
502 pregnant women
10.8% seroprevalence  
of HSV-2
Commer-cial ELISA 
to detect IgG
Haddow et al, 2007 (56)
Vanuatu,  
antenatal clinic
Cross sectional study,  
1 to 2 years
535 pregnant women
32% seroprevalence  
of HSV-2
ELISA
Joesoef et al, 1996 (65)
Indonesia,  
prenatal clinic
Cross sectional study,  
15 months
599 pregnant women
9.9% seroprevalence  
of HSV-2
Immuno-blot
ELISA – enzyme-linked immunosorbent assay
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atitis B and C), due to limited resources or expertise. These 
infrastructural problems are essential contributors to the 
persistence of high maternal morbidity and mortality in 
developing countries and need to be overcome in order to 
accurately characterize the burden of maternal infections 
in these countries.
Strengths and limitations
This is one of the first reviews to summarise the epidemi-
ology of bacterial and viral maternal infections in the de-
veloping world (7). The search strategy devised is sensitive 
and specific, which allowed for a comprehensive review of 
available literature on this topic. The information gener-
ated in this review can be utilised to guide public health 
policy and the allocation of resources within local govern-
ments and by the international community towards im-
proving maternal health. Limitations of this work include 
the exclusion of studies with less than 500 participants and 
the omission of pathogens with less than 5 papers report-
ing their prevalence. This was done to minimise the poten-
tial confounding effect that smaller, underpowered studies 
may have had on the overall prevalences reported and to 
increase the statistical robustness of the data presented.
This study could be further improved by analysing smaller 
studies that were identified and performing a sensitivity 
analysis of their results prior to inclusion. Also, it is likely 
that further valuable insights may be obtained from non-
English articles of studies conducted in francophone parts 
of Africa (in French), South America (in Spanish) and in 
China (in Chinese), which could be accessed from appro-
priate databases. Reviewing non-English articles may assist 
in defining the epidemiology of pathogens for which we 
managed to identify few (<5) studies, as well as providing 
more robust data on the pathogens presented in this review. 
In addition, searching grey (unpublished) literature or con-
tacting health officials and researchers in the field may also 
yield more country specific data on the subject, thus en-
abling more targeted and context-specific public health 
measures.
Recommendations and future work
Reducing the prevalence of maternal infections, and con-
sequently maternal and neonatal morbidity and mortality, 
requires a concerted, multifaceted approach. Improve-
ments in the provision, accessibility and uptake of antena-
tal care services are absolutely essential to reduce the prev-
alence of not only maternal infection but also other causes 
of maternal morbidity and mortality. This entails an im-
provement in antenatal booking, the number of antenatal 
visits and childbearing with professional assistance (40). 
Wherever possible, routine screening and treatment for 
maternal infections should be conducted. Alternatives to 
antenatal screening include syndromic management or risk 
assessment based approaches to treat maternal infection. 
Routine immunisation against vaccine-preventable diseas-
es should also be implemented to reduce the eventual bur-
den that these infections may have on pregnancy outcomes 
and neonates (7,132).
We hope that the gaps in information highlighted in this 
study will guide the design and implementation of studies 
to accurately assess the epidemiology of maternal infections 
in the developing world, especially in countries where the 
prevalence of maternal infection is unreported. Ideally, 
studies should be large, community-based and longitudi-
nal, and investigate the association between pregnancy out-
come and microbiological and serological evidence of ma-
ternal infection to accurately define the burden of maternal 
infections and their impact on pregnancy outcome (132). 
There is also a great need for the design of rapid point-of-
care diagnostic tests for use in the field for the diagnosis of 
maternal infections. Affordable and novel therapeutics and 
interventions will also be beneficial in reducing the impact 
of maternal infections. These measures are dependent upon 
the co-operation of the research community and the altru-
ism of industry to succeed.
More than US$ 40 billion (€ 30 billion) has been pledged 
towards the newly formed Global Strategy for Women’s and 
Children’s Health (169). These funds should be spent pru-
dently on effective and sustainable measures to improve ma-
ternal health. The majority of this allocation should go to-
wards the strengthening of basic antenatal care systems in 
developing countries. Because serious maternal infections 
are a major contributor to maternal morbidity and mortality, 
the early detection and treatment of infections is an impor-
tant component of prenatal care. The continued support of 
the global community is also needed to ensure the improve-
ment of maternal health in the developing world.
CONCLUSION
This review highlights the high bacterial and viral maternal 
infection rates in the developing world. Urgent, concerted 
action is required to reduce the burden of these infections. 
In addition to raising awareness about the severity of the 
problem of maternal infections in the developing world, 
data from this review will be beneficial in guiding public 
health policy, research interests and donor funding towards 
achieving MDG 5.
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